Home › MetaStat Announces Commencement Of Its Comprehensive Drug Development Program With Significant New Hires And Research Facility Opening
 

Keywords :   


MetaStat Announces Commencement Of Its Comprehensive Drug Development Program With Significant New Hires And Research Facility Opening

2013-10-02 06:24:58| drugdiscoveryonline News Articles

MetaStat Inc., a life science company focused on understanding and treating systemic metastasis, recently announced that it has commenced its comprehensive drug development program with the hiring of Elizabeth Buck, Ph.D. and Matthew O'Connor, both formerly of OSI Pharmaceuticals, Inc. (acquired by Astellas Pharma, Inc.), along with the opening of its new drug discovery research facility located in Stony Brook, NY. Both Dr. Buck and Mr. O'Connor will work closely and in collaboration with Dr. David Epstein, MetaStat's Head of Drug Development and former Chief Scientific Officer of OSI Pharmaceuticals

Tags: research development program significant

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
13.05Dantex announces new digital director for Pico division
13.05Tonny De Beer Joins First Quality
13.05Join us for the 2024 Global Hog Industry Virtual Conference
13.05New version of Chat-GPT can teach maths and flirt
13.05Eastern North Pacific Tropical Weather Outlook
13.05Melinda French Gates to quit Gates Foundation
13.05BASF in South Carolina Joins with Make-A-Wish
13.05PCMC addresses latest printing trends at \'Power Packs Live\'
More »